Quest Diagnostics Inc (DGX) 71.68 $DGX
Uptrend Call Working As Quest Diagnostics Stock Rises 17.5% (DGX)
Comtex SmarTrend(R) - Fri Feb 13, 4:44PM CST
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on October 22nd, 2014 at $61.01. In approximately 4 months, Quest Diagnostics has returned 17.49% as of today's recent price of $71.68.
DGX: 71.68 (+0.03)
Quest Diagnostics Set to Possibly Pullback After Yesterday's Rally of 1.52%
Comtex SmarTrend(R) - Wed Feb 11, 4:34PM CST
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $70.33 to a high of $71.55. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $71.53 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DGX: 71.68 (+0.03)
SmarTrend Watching for Potential Pullback in Shares of Quest Diagnostics After 1.52% Gain
Comtex SmarTrend(R) - Wed Feb 11, 4:34PM CST
Quest Diagnostics (NYSE GX) traded in a range yesterday that spanned from a low of $70.33 to a high of $71.55. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $71.53 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
DGX: 71.68 (+0.03)
These 5 Hated Stocks Could Pop in February: AT&T, Quest Diagnostics and More
at The Street - Wed Feb 11, 6:00AM CST
These heavily shorted stocks could get squeezed much higher on any positive catalyst.
VRSN: 62.15 (+0.43), T: 34.66 (+0.05), DLR: 68.65 (-2.07), RMD: 66.25 (+0.79), DGX: 71.68 (+0.03)
Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation
PR Newswire - Mon Feb 09, 7:45AM CST
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation.
DGX: 71.68 (+0.03)
Quest Diagnostics Strong on Earnings, Long-Term Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 10:32AM CST
On Feb 5, 2015, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
USPH: 41.08 (+0.07), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Why Quest Diagnostics (DGX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 7:44AM CST
Quest Diagnostics (DGX)in the Medical-Healthcare space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
DGX: 71.68 (+0.03)
PossAbilities receives $1 million from Quest Diagnostics for title sponsorship
PRWeb - Fri Jan 30, 4:30PM CST
Loma Linda University Health (LLUH) PossAbilities was presented with a check on Wednesday, Jan. 28 for $1 million from its new title sponsor, Quest Diagnostics, one of the world's leading providers of diagnostic testing, information and services.
DGX: 71.68 (+0.03)
16.1% Return Seen to Date on SmarTrend Quest Diagnostics Call (DGX)
Comtex SmarTrend(R) - Fri Jan 30, 9:53AM CST
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE GX) on October 22nd, 2014 at $61.01. In approximately 3 months, Quest Diagnostics has returned 16.14% as of today's recent price of $70.86.
DGX: 71.68 (+0.03)
Quest Diagnostics Q4 Earnings, Revenues Beat; Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 2:37PM CST
Quest Diagnostics' (DGX) fourth-quarter 2014 adjusted earnings per share (EPS) from continuing operations of $1.08 exceeded the Zacks Consensus Estimate by 3 cents.
AMSG: 55.56 (+0.48), RDNT: 8.66 (-0.11), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16)
Quest Diagnostics (DGX) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Thu Jan 29, 1:59PM CST
The following Quest Diagnostics (DGX) conference call took place on January 29, 2015, 08:30 AM ET. This is a transcript of that earnings call:
DGX: 71.68 (+0.03)
Quest Diagnostics' (DGX) CEO Steve Rusckowski on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 12:36PM CST
DGX: 71.68 (+0.03)
Quest Q4 earnings up 33%
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 9:55AM CST
DGX: 71.68 (+0.03)
Quest Diagnostics (DGX) Beat On Q4 Earnings and Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 8:17AM CST
Quest Diagnostics (DGX) Beat On Q4 Earnings and Revenues
DGX: 71.68 (+0.03)
Quest Diagnostics Incorporated (DGX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 29, 7:25AM CST
DGX: 71.68 (+0.03)
Quest Diagnostics tops Street 4Q forecasts
Automated Insights - Thu Jan 29, 6:52AM CST
MADISON, N.J. (AP) _ Quest Diagnostics Inc. (DGX) on Thursday reported fourth-quarter earnings of $190 million.
DGX: 71.68 (+0.03)
RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting
GlobeNewswire - Thu Jan 29, 6:13AM CST
-- RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program
RDHL: 12.69 (+0.04), DGX: 71.68 (+0.03)
Quest Diagnostics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 6:11AM CST
DGX: 71.68 (+0.03)
Quest Diagnostics Reports Fourth Quarter and Full Year 2014 Financial Results; Provides Guidance For Full Year 2015; Increases Dividend 15%
PR Newswire - Thu Jan 29, 6:00AM CST
-- Fourth quarter revenues from continuing operations of $1.9 billion, up 7.2% versus prior year
DGX: 71.68 (+0.03)
Uptrend Call Working As Quest Diagnostics Stock Rises 17.5% (DGX)
Comtex SmarTrend(R) - Fri Feb 13, 4:44PM CST
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on October 22nd, 2014 at $61.01. In approximately 4 months, Quest Diagnostics has returned 17.49% as of today's recent price of $71.68. DGX: 71.68 (+0.03)
Quest Diagnostics Set to Possibly Pullback After Yesterday's Rally of 1.52%
Comtex SmarTrend(R) - Wed Feb 11, 4:34PM CST
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $70.33 to a high of $71.55. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $71.53 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DGX: 71.68 (+0.03)
SmarTrend Watching for Potential Pullback in Shares of Quest Diagnostics After 1.52% Gain
Comtex SmarTrend(R) - Wed Feb 11, 4:34PM CST
Quest Diagnostics (NYSE
GX) traded in a range yesterday that spanned from a low of $70.33 to a high of $71.55. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of $71.53 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious. DGX: 71.68 (+0.03)
These 5 Hated Stocks Could Pop in February: AT&T, Quest Diagnostics and More
at The Street - Wed Feb 11, 6:00AM CST
These heavily shorted stocks could get squeezed much higher on any positive catalyst.
VRSN: 62.15 (+0.43), T: 34.66 (+0.05), DLR: 68.65 (-2.07), RMD: 66.25 (+0.79), DGX: 71.68 (+0.03)
Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation
PR Newswire - Mon Feb 09, 7:45AM CST
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation.
DGX: 71.68 (+0.03)
Quest Diagnostics Strong on Earnings, Long-Term Prospects - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 10:32AM CST
On Feb 5, 2015, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
USPH: 41.08 (+0.07), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16), HLS: 45.01 (+0.30)
Why Quest Diagnostics (DGX) Stock Might be a Great Pick - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 7:44AM CST
Quest Diagnostics (DGX)in the Medical-Healthcare space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective
DGX: 71.68 (+0.03)
PossAbilities receives $1 million from Quest Diagnostics for title sponsorship
PRWeb - Fri Jan 30, 4:30PM CST
Loma Linda University Health (LLUH) PossAbilities was presented with a check on Wednesday, Jan. 28 for $1 million from its new title sponsor, Quest Diagnostics, one of the world's leading providers of diagnostic testing, information and services.
DGX: 71.68 (+0.03)
16.1% Return Seen to Date on SmarTrend Quest Diagnostics Call (DGX)
Comtex SmarTrend(R) - Fri Jan 30, 9:53AM CST
SmarTrend identified an Uptrend for Quest Diagnostics (NYSE
GX) on October 22nd, 2014 at $61.01. In approximately 3 months, Quest Diagnostics has returned 16.14% as of today's recent price of $70.86. DGX: 71.68 (+0.03)
Quest Diagnostics Q4 Earnings, Revenues Beat; Grow Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 2:37PM CST
Quest Diagnostics' (DGX) fourth-quarter 2014 adjusted earnings per share (EPS) from continuing operations of $1.08 exceeded the Zacks Consensus Estimate by 3 cents.
AMSG: 55.56 (+0.48), RDNT: 8.66 (-0.11), DGX: 71.68 (+0.03), AMED: 28.62 (+0.16)
Quest Diagnostics (DGX) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Thu Jan 29, 1:59PM CST
The following Quest Diagnostics (DGX) conference call took place on January 29, 2015, 08:30 AM ET. This is a transcript of that earnings call:
DGX: 71.68 (+0.03)
Quest Diagnostics' (DGX) CEO Steve Rusckowski on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Jan 29, 12:36PM CST
DGX: 71.68 (+0.03)
Quest Q4 earnings up 33%
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 9:55AM CST
DGX: 71.68 (+0.03)
Quest Diagnostics (DGX) Beat On Q4 Earnings and Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 8:17AM CST
Quest Diagnostics (DGX) Beat On Q4 Earnings and Revenues
DGX: 71.68 (+0.03)
Quest Diagnostics Incorporated (DGX) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Jan 29, 7:25AM CST
DGX: 71.68 (+0.03)
Quest Diagnostics tops Street 4Q forecasts
Automated Insights - Thu Jan 29, 6:52AM CST
MADISON, N.J. (AP) _ Quest Diagnostics Inc. (DGX) on Thursday reported fourth-quarter earnings of $190 million.
DGX: 71.68 (+0.03)
RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting
GlobeNewswire - Thu Jan 29, 6:13AM CST
-- RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program
RDHL: 12.69 (+0.04), DGX: 71.68 (+0.03)
Quest Diagnostics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 6:11AM CST
DGX: 71.68 (+0.03)
Quest Diagnostics Reports Fourth Quarter and Full Year 2014 Financial Results; Provides Guidance For Full Year 2015; Increases Dividend 15%
PR Newswire - Thu Jan 29, 6:00AM CST
-- Fourth quarter revenues from continuing operations of $1.9 billion, up 7.2% versus prior year
DGX: 71.68 (+0.03)
